COMP <GO>
ICCC vs JNJ // REVENUE GROWTH (YOY)
ImmuCell Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ICCC 0
— JNJ 10
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
revenue-growth
4.30%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICCC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICCC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.40% | 67.90% | -26.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.20% | 25.50% | -21.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.9x | 18.5x | +17.40 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.31% | 2.97% | -1.66 | JNJ | /fcf-yield <GO> |
| Operating Margin | 6.00% | 34.70% | -28.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -3.80% | 28.50% | -32.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 4.30% | 6.00% | -1.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.28 | 5.59 | -1.31 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.8 | 62.1 | -10.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $93.7M | $662.49B | -$662.40B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICCC REV | JNJ REV | ICCC GROSS % | JNJ GROSS % | ICCC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.6M | $94.19B | 41.4% | 67.9% | $1.2M | $19.70B |
| FY 2024 | $26.5M | $88.82B | 30.0% | 69.1% | -$107.8K | $19.84B |
| FY 2023 | $17.5M | $85.16B | — | — | -$4.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICCC // BETA —
JNJ // BETA 1.08